The US Centers for Medicare and Medicaid Services’ description of the maximum fair price determination process for the first 10 drugs in the Medicare negotiation program offered little additional insight into how the agency developed price offers or the manufacturer information and arguments the agency found most persuasive.
Hidden Figures: Medicare Price Negotiation Post-Mortem Offers Few New Insights
The much-anticipated report from the US Centers for Medicare and Medicaid Services is heavily redacted and lacks a specific justification for the prices, but preserves agency flexibility to shape the program going forward.
More from Medicare
More from Geography
• By
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.
• By
Organizational turmoil has not yet affected reviews of novel agent applications, with Q1 2025 approvals coming in low, but the first quarter share of the entire year is variable.